Clinical Activity of Vinflunine in Transitional Cell Carcinoma of the Urothelium and Other Solid Tumors

Seminars in Oncology

Volumn 35, Issue SUPPL 3, 2008, Pages

  Bellmunt, Joaquim ^a   Delgado, Francois Michel ^b   George, Claude ^c  

^a HOSPITAL DEL MAR   (Spain)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 O DEACETYLVINFLUNINE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; TRASTUZUMAB; VINFLUNINE;

ABDOMINAL PAIN; ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER CONTROL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONSTIPATION; DIARRHEA; DRUG BINDING; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; INJECTION SITE REACTION; LEUKOPENIA; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SENSORY NEUROPATHY; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT FAILURE; TREATMENT RESPONSE; URINARY TRACT CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; MESOTHELIOMA; MICE; PLEURAL NEOPLASMS; TUBULIN MODULATORS; URINARY BLADDER NEOPLASMS; UROTHELIUM; VINBLASTINE;

EID: 44449116079     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.01.008     Document Type: Article

References (52)

1. Jordan M.A., and Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 4 (2004) 253-265
2. Zhou J., and Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 5 (2005) 65-71
3. Fahy J., Duflos A., Ribet J.P., et al. Vinca alkaloids in superacidic media: a method for creating a new family of antitumor derivatives. J Am Chem Soc 119 (1997) 8576-8577
4. Fahy J. Modifications in the "upper" velbenamine part of the Vinca alkaloids have major implications for tubulin interacting activities. Curr Pharm Des 7 (2001) 1181-1197
5. Kruczynski A., Colpaert F., Tarayre J.P., Mouillard P., Fahy J., and Hill B.T. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol 41 (1998) 437-447
6. Kruczynski A., Barret J.M., Etievant C., Colpaert F., Fahy J., and Hill B.T. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol 55 (1998) 635-648
7. Lobert S., Ingram J.W., and Correia J.J. The thermodynamics of vinca alkaloid-induced tubulin spirals formation. Biophys Chem 126 (2007) 50-58
8. Barret J.M., Etievant C., and Hill B.T. In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs. Cancer Chemother Pharmacol 45 (2000) 471-476
9. Bennouna J., Fumoleau P., Armand J.P., et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol 14 (2003) 630-637
10. Bennouna J., Campone M., Delord J.P., and Pinel M.C. Vinflunine: A novel antitubulin agent in solid malignancies. Expert Opin Invest Drugs 14 (2005) 1259-1267
11. Johnson P., Geldart T., Fumoleau P., Pinel M.C., Nguyen L., and Judson I. Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Invest New Drugs 24 (2006) 223-231
12. Bonfil R.D., Russo D.M., Binda M.M., Delgado F.M., and Vincenti M. Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. Urol Oncol 7 (2002) 159-166
13. Culine S., Theodore C., De Santis M., et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 94 (2006) 1395-1401
14. Vaughn D.J., Srinivas S., Stadler W.M., Pili R., Petrylak D., De Marco S., et al. Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU). [Abstract 15543]. J Clin Oncol 25 18S (2007) 653s
15. Petrylak D.P., Vaughn D.J., Srinivas S., Pili R., Stadler W., Sternberg C., et al. Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU). Eur J Cancer Suppl 5 (2007) 309 (Abstr 4534)
16. Dash A., Galsky M.D., Vickers A.J., et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107 (2006) 506-513
17. Galsky M., Sonpavde G., and Hutson T.E. Current management of bladder cancer. US Oncological Disease 6 (2006) 62-66
18. Bernard-Marty C., Cardoso F., and Piccart M.J. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 9 (2004) 617-632
19. Campone M., Cortes-Funes H., Vorobiof D., et al. Vinflunine: A new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer 95 (2006) 1161-1166
20. Fumoleau P., Campone M., Vorobiof D., Casado M., Ruff P., Khoo Kei S., et al. Phase II study of i.v. vinflunine as second line in patients with metastatic breast cancer after anthracycline-taxane failure. J Clin Oncol 22 (2004) 329 (abstr 542)
21. Campone M., Fumoleau P., Roche H., et al. A dose-finding and pharmacokinetic study of I.V. vinflunine (VFL) in combination with capecitabine (CAPE) as second line treatment of metastatic breast cancer (MBC) (2006) Proceedings of the San Antonio Breast Cancer Symposium; December 14; San Antonio, TX
22. Fumoleau P., Largillier R., Clippe C., et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40 (2004) 536-542
23. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 719-726
24. Paridaens R., Wildiers H., Dalenc F., Rixe O., Cadic V., Pinel M., et al. Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer. J Clin Oncol 25 (2007) 1020 (abstr 1058)
25. Peacock N.W., Spigel D.R., Mainwaring P.N., Thompson D.S., Simons L., Rubin M.S., et al. Preliminary results of a multicenter phase II trial of vinflunine (with trastuzumab in HER2+ pts) as first-line treatment in metastatic breast cancer cancer. [abstract 1043]. J Clin Oncol 28 18S (2007) 42s
26. Brodowicz T., Krzakowski M., Zwitter M., et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer 52 (2006) 155-163
27. Kelly K., Crowley J., Bunn P.A.J., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19 (2001) 3210-3218
28. Sandler A.B., Nemunaitis J., Denham C., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18 (2000) 122-130
29. Kumar A., and Wakelee H. Second- and third-line treatments in non-small cell lung cancer. Curr Treat Options Oncol 7 (2006) 37-49
30. Bozcuk H., Dalmis B., Samur M., Ozdogan M., Artac M., and Savas B. Quality of life in patients with advanced non-small cell lung cancer. Cancer Nurs 29 (2006) 104-110
31. Bennouna J., Breton J.L., Tourani J.M., et al. Vinflunine - an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Br J Cancer 94 (2006) 1383-1388
32. Krzakowski M., Douillard J., Ramlau R., Jassem J., Szczesna A., Zatloukal P., et al. Phase III study of vinflunine versus docetaxel in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen. J Clin Oncol 25 (2007) 4278 (abstr 7511)
33. Bennouna J., Breton J.L., Tourani J.M., Ottensmeier C., O'Brien M., Kosmidis P., et al. Vinflunine - an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Br J Cancer 94 (2006) 1383-1388
34. Ramlau R., Souquet P.-J., Sun X., Lopez-Vivanco G., Afenjar K., Colin C., et al. Results of a phase I/II and pharmacokinetic study of vinflunine (VFL) in combination with cisplatin (CDDP) for primary treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 22 (2004) 2723 (abstr 7110)
35. Tourani J., Pinel M., Planchard D., Aslanis V., Gouva S., and Robinet G. Phase I and pharmacokinetic study of Vinflunine (VFL) in combination with carboplatin (CBDCA) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): Final results. [abstract 7271]. J Clin Oncol 23 16S (2005) 688s
36. Tourani J., Pinel M., Planchard D., Aslanis V., Gouva S., Robinet G., et al. Phase I and pharmacokinetic study of Vinflunine (VFL) in combination with carboplatin (CBDCA) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): Final results. J Clin Oncol 23 (2005) (abstr 7271)
37. Blackhall F.H., and Shepherd F.A. Small cell lung cancer and targeted therapies. Curr Opin Oncol 19 (2007) 103-108
38. Murray N., and Turrisi III A.T. A review of first-line treatment for small-cell lung cancer. J Thorac Oncol 1 (2006) 270-278
39. MacCallum C., and Gillenwater H.H. Second-line treatment of small-cell lung cancer. Curr Oncol Rep 8 (2006) 258-264
40. Peyton J.D., Spigel D.R., Hainsworth J.D., Yardley D.A., Burris H.A., Vazquez E., et al. Phase II trial of vinflunine in patients with relapsed small cell lung cancer. J Clin Oncol 25 (2007) (abstr 18091)
41. Masters G.A., Declerck L., Blanke C., et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 21 (2003) 1550-1555
42. Smit E.F., Fokkema E., Biesma B., Groen H.J., Snoek W., and Postmus P.E. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 77 (1998) 347-351
43. Eckardt J.R., von Pawel J., Pujol J.L., Papai Z., Quoix E., Ardizzoni A., et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25 (2007) 2086-2092
44. Steele J.P., and Klabatsa A. Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol 16 (2005) 345-351
45. Lerner H.J., Schoenfeld D.A., Martin A., Falkson G., and Borden E. Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 52 (1983) 1981-1985
46. Zidar B.L., Green S., Pierce H.I., Roach R.W., Balcerzak S.P., and Militello L. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study. Invest New Drugs 6 (1988) 223-226
47. Vogelzang N.J., Goutsou M., Corson J.M., et al. Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 27 (1990) 239-242
48. Steele J.P., Shamash J., Evans M.T., Gower N.H., Tischkowitz M.D., and Rudd R.M. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18 (2000) 3912-3917
49. Scagliotti G.V., Shin D.M., Kindler H.L., et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21 (2003) 1556-1561
50. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
51. Talbot D.C., Margery J., Dabouis G., et al. Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol 25 (2007) 4751-4756
52. Paule B., Saliba F., Gil-Delgado M., Puozzo C., Favrel S., Ravaud A., et al. Phase I and pharmacokinetic (PK) dose-adjusted study of IV vinflunine (VFL) in cancer patients with liver dysfunction (LD): Pharmacokinetic results. J Clin Oncol 15 18S (2007) 102s (abstr 2423)